| Identification | Back Directory | [Name]
3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone | [CAS]
503615-03-0 | [Synonyms]
Apixaban Impurity 19
Apixaban Intermediate3
5-morpholin-4-yl-1-(4-nitrophenyl)-2,3-dihydropyridin-6-one
3-Morpholino-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one
3-(4-Morpholinyl)-1-(4-nitrophenyl)-5,6-dihydro-2(1H)-pyridinone
5,6-Dihydro-3-(4-morpholinyl)-1-(4-nitrophenyl)-2(1H)-pyridinone
3-(Morpholin-4-yl)-1-(4-nitrophenyl)-5,6-dihydropyridin-2(1H)-one (Nitro MPDP) | [Molecular Formula]
C15H17N3O4 | [MDL Number]
MFCD19440872 | [MOL File]
503615-03-0.mol | [Molecular Weight]
303.313 |
| Chemical Properties | Back Directory | [Boiling point ]
506.5±50.0 °C(Predicted) | [density ]
1.356 | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
Chloroform (Slightly), Methanol (Slightly, Heated) | [form ]
Solid | [pka]
3.11±0.20(Predicted) | [color ]
Light Yellow | [InChI]
InChI=1S/C15H17N3O4/c19-15-14(16-8-10-22-11-9-16)2-1-7-17(15)12-3-5-13(6-4-12)18(20)21/h2-6H,1,7-11H2 | [InChIKey]
LBFAEOWNWSDWRZ-UHFFFAOYSA-N | [SMILES]
C1(=O)N(C2=CC=C([N+]([O-])=O)C=C2)CCC=C1N1CCOCC1 |
| Questions And Answer | Back Directory | [Description]
3-(4-Morpholinyl)-1-(4-nitrophenyl)-5, 6-dihydro-2(1H)-pyridinone is the intermediate for the synthesis of apixaban, which is an anticoagulant for the treatment of venous thromboembolic events.
| [References]
Chao, H. E., et al. "Synthesis of Apixaban." Chinese Journal of Pharmaceuticals (2014).
https://en.wikipedia.org/wiki/Apixaban
|
| Hazard Information | Back Directory | [Uses]
3-(Morpholinyl)-N-(4-nitrophenyl)-5,6-dihydropyridin-2-one is a reagent in the synthesis of 4,5-dehydro Apixaban (D229385) an impurity of Apixaban (A726700), a potent, direct, selective, and orally active inhibitor of coagulation factor Xa. It is a potential new oral coagulant that may be useful prevention of venous thromboembolism in total hip, knee replacement orthopedic surgery and stroke in treatment of patient with venous thromboembolic disorder or with atrial fibrillation |
|
|